With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Stock index futures jumped on Tuesday, as the July retail inflation report came largely in line, but core CPI was slightly ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

Dividend stocks are a time-tested way to retire or protect your portfolio if you are already retired. Their yield can give ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a bigger player in oncology. Sales for bladder cancer drug Padcev, lung cancer ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has ...